Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-80
SponsorFinis Terrae University

About this trial

The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participants are able to provide signed and dated written informed consent prior to any study specific procedures

Aged ≥ 60 and ≤ 80 years

Body mass index (BMI) 25 - 35 kg/m2

Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)

Disqualifiers

Patients with congestive heart failure and and/or severe renal and or liver insufficiency

Uncontrolled hypertension

Any contra-indication for MRI scanning

Alcohol consumption of > 3 servings per day for man and >2 servings per day for woman

Trial design

Design model

Parallel

Treatments tested in this trial

  • Nicotinamide Riboside (NR)

    Dietary supplement

    Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program

  • Placebo

    Dietary supplement

    Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program

Treatment groups

28 Participants
are divided into 2 treatment groups
Group A: NR+EXTRExperimental treatment 1 intervention
Group B: PLA+EXTRPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Skeletal muscle mitochondrial respiratory capacity

Skeletal muscle mitochondrial respiratory capacity will be measured in permeabilized fibres.

Time frame
12 weeks

Secondary outcomes

1

Quantification of proteins that regulate oxidative metabolism

Quantification of proteins content of oxidative phosphorylation system in muscle biopsies

Time frame
12 weeks
2

Skeletal muscle mitochondrial content

Proteins content of oxidative phosphorylation system will be quantified from muscle biopsy

Time frame
12 weeks
3

Maximal aerobic capacity

Maximal aerobic capacity will be measure upon a progressive cycling test

Time frame
12 weeks
4

Walking speed and distance

Walking speed and distance will be measured via the 6-minutes walking test

Time frame
12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.